Home » Newsletters » BioWorld Science

BioWorld Science

June 16, 2014

View Archived Issues

Preclinical safety of [18F]FBYBF-2 validates dosimetric studies in humans

Sterna Biologicals presents first-in-class GATA-3-targeting DNAzymes

Preclinical and clinical data reported for PI3K-alpha kinase inhibitor in various cancers

Merck Serono and MorphoSys collaborate on immune-oncology

Horizon Discovery licenses CRISPR gene editing system

CQDM and Sanofi Canada form drug discovery partnership

Hyperion Therapeutics acquires Andromeda Biotech

AnGes signs agreement with Quintiles for phase III study of Collategene

Circassia discloses positive data from phase IIb dust mite allergy trial

ViiV Healthcare and Janssen to develop single-tablet regimen for HIV

FDA removes clinical hold on imetelstat myelofibrosis trial

Oncobiologics begins phase I trial of biosimilar ONS-3010

Bayer Schering Pharma discloses novel Mnk1 inhibitors

Parion and Santen sign option agreement for P-321 in Asia

EntreMed changes name

Phase I results on OPB-51602 in relapsed/refractory hematological malignancies

Boehringer Ingelheim patents BRD4 inhibitors

Esteve patent describes novel sigma1 receptor ligands

Merck & Co. prepares and tests novel PDE10A inhibitors

OncoMed halts enrollment and dosing in phase I trials of vantictumab and Fzd8-Fc

FDA approves Lymphoseek for use in head and neck cancer

Roche presents new TRPA1 antagonists

Celgene exercises option to license AG-221 under Agios collaboration

KalGene to collaborate with multiple organizations on biomarker and treatment for aggressive cancers

Phase IIb trial of CRS-207 and GVAX Pancreas vaccines opens for recruiting

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...